Finasteride
Indication
Benign Prostatic Hyperplasia
BJUI - Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia
Green
Brand:
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Finasteride is the preferred 1st line 5α-reductase inhibitor for Benign Prostatic Hyperplasia (BPH) within the Lancashire ad South Cumbria Health Economies. This is because:
-
Finasteride is significantly less expensive than the alternative 5‑α reductase inhibitor dutasteride.
-
The Enlarged Prostate International Comparator Study (EPICS) found, when dutasteride or finasteride were administered for 12 months, they were similarly effective at 3 months and 12 months in reducing prostate volume, improving Qmax and urinary symptoms associated with BPH.
-
Additionally the EPICS study also found no difference in overall numbers of adverse events between finasteride and dutasteride.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: